Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $20.7 Million - $28.2 Million
300,000 New
300,000 $21.1 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $59.3 Million - $74 Million
-798,500 Reduced 90.39%
84,900 $6.55 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $45.6 Million - $53.7 Million
564,400 Added 176.93%
883,400 $78.8 Million
Q3 2017

Nov 14, 2017

BUY
$80.6 - $94.95 $25.7 Million - $30.3 Million
319,000
319,000 $29.7 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.